North Carolina is currently home to 2618 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Durham, Charlotte, Winston-Salem and Chapel Hill. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
NCT05646381
Recruiting
The purpose of this study is to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) administered subcutaneously once monthly compared to placebo in slowing the progression of calcific aortic valve stenosis.
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
04/14/2025
Locations: Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina
Conditions: Aortic Stenosis
Register for Updates
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
NCT05618028
Recruiting
B-cell malignancies are a group of cancers of B lymphocytes, a type of white blood cell responsible for fighting infections. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-525 as a monotherapy. ABBV-525 is an investigational drug being developed for the treatment of B-Cell Malignancies. Study doctors put the participants in groups called treatment arms. Participants will receive ABBV-525 at different doses. Approximately 100 adult... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Levine Cancer Institute /ID# 246363, Charlotte, North Carolina
Conditions: Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, B Cell Malignancies, Non-Hodgkin's Lymphoma
Register for Updates
Virtual Reality Mindfulness Meditation After ACL Reconstruction
NCT05527171
Recruiting
To evaluate the effect of virtual reality mindfulness meditation on patients after ACLR, the investigators will determine the effect of virtual reality mindfulness meditation to 1) decrease self-reported injury-related fear, 2) improve poor jump-landing movement patterns, and 3) improve brain activity in women 1 to 5 years post-ACLR when compared to a virtual reality sham group.
Gender:
FEMALE
Ages:
Between 14 years and 25 years
Trial Updated:
04/14/2025
Locations: Fetzer Hall, 210 South Road, Chapel Hill, North Carolina
Conditions: Anterior Cruciate Ligament Injury
Register for Updates
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer
NCT05451004
Recruiting
This study is being done to answer the following question: Is the chance of cancer spreading or returning the same if radiotherapy to the neck is guided, by using a special imaging study called lymph node mapping (lymphatic mapping) Single Photon Emission Computed Tomography (SPECT-CT), compared to the usual treatment when radiotherapy is given to both sides of the neck?
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Conditions: Oropharyngeal Cancer
Register for Updates
COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide
NCT05434689
Recruiting
Similar to the paradigm established in other hematologic malignancies that are considered curable, the achievement of MRD(-) status is necessary for long term disease control in MM. The fact that the majority of patients remain MRD (+) after induction therapy and AHCT points to the opportunity to deploy novel agents with complementary mechanism of action and favorable toxicity profile to reach and maintain MRD (-) status. Given its favorable toxicity profile, the convenience of oral administrat... Read More
Gender:
ALL
Ages:
19 years and above
Trial Updated:
04/14/2025
Locations: Duke University, Durham, North Carolina
Conditions: Multiple Myeloma
Register for Updates
Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD
NCT05346354
Recruiting
The primary purpose of this study is to evaluate the safety and efficacy of ravulizumab in pediatric participants with Neuromyelitis Optica Spectrum Disorder (NMOSD).
Gender:
ALL
Ages:
All
Trial Updated:
04/14/2025
Locations: Research Site, Durham, North Carolina
Conditions: Neuromyelitis Optica Spectrum Disorder
Register for Updates
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
NCT05243797
Recruiting
This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem cell transplant.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Levine Cancer Institute, Charlotte, North Carolina
Conditions: Multiple Myeloma
Register for Updates
A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
NCT05155332
Recruiting
This study is open to adults with different types of advanced cancer (solid tumors) that are accessible for injection and/or biopsy. This is a study for people with a life expectancy of at least 3 months after starting study treatment. The purpose of this study is to find the highest dose of a medicine called BI 1831169 that people with advanced cancer can tolerate when taken with or without a type of antibody called a checkpoint inhibitor (anti-PD-1 antibody). Another purpose is to check whethe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina
Conditions: Solid Tumors
Register for Updates
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
NCT05096481
Recruiting
This study will address the question of whether targeting CMV antigens with PEP-CMV can serve as a novel immunotherapeutic approach in pediatric patients with newly-diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG) as well as recurrent medulloblastoma (MB). PEP-CMV is a vaccine mixture of a peptide referred to as Component A. Component A is a synthetic long peptide (SLP) of 26 amino acid residues from human pp65. The SLPs encode multiple potential class I, class II, a... Read More
Gender:
ALL
Ages:
Between 3 years and 39 years
Trial Updated:
04/14/2025
Locations: Duke Cancer Center, Durham, North Carolina
Conditions: High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Recurrent Medulloblastoma
Register for Updates
Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis
NCT05047172
Recruiting
The primary goal of the trial is to determine if the experimental arms (rivaroxaban or ticagrelor or both) are superior to the clopidogrel arm for lowering the 1-year rate of ischemic stroke, intracerebral hemorrhage, or vascular death.
Gender:
ALL
Ages:
30 years and above
Trial Updated:
04/14/2025
Locations: Carolinas Medical Center, Charlotte, North Carolina
Conditions: Intracranial Arteriosclerosis, Stroke
Register for Updates
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
NCT04613596
Recruiting
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates for first-line treatment. The Phase 3 portion of the study compares the efficacy of adagrasib in combination with pembrolizumab versus pembrolizumab in patients with unresectable, locally advanced or metastatic squamous or nonsquamous NSCLC with KRAS G12C mutati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
Register for Updates
A Phase 1B/2 Study of RP1 in Solid Organ Transplant Patients With Advanced Cutaneous Malignancies
NCT04349436
Recruiting
This Phase 1B/2 study is a multicenter, open-label, study of RP1 to investigate the (a) objective response rate, in addition to (b) safety and tolerability of RP1 for the treatment of advanced cutaneous malignancies in up to 65 evaluable organ transplant recipients. This will include patients with either previous renal, hepatic, heart, lung, or other solid organ transplantation or hematopoietic cell transplant and experiencing subsequent documented locally advanced or metastatic cutaneous malign... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Conditions: Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Basal Cell Carcinoma, Melanoma
Register for Updates